key: cord-0812534-1vtyqctk authors: Case, Siobhan Mary; Son, Mary Beth title: COVID-19 in Pediatrics date: 2021-07-21 journal: Rheum Dis Clin North Am DOI: 10.1016/j.rdc.2021.07.006 sha: 7e10d3935297efac65c13a2b1e0efccfd03d40d5 doc_id: 812534 cord_uid: 1vtyqctk This chapter reviews the diagnosis and treatment of infection with coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), as well as a new inflammatory syndrome following SARS CoV-2 infection, called Multisystem Inflammatory Syndrome in Children (MIS-C). respiratory support. 13 Obesity is associated with higher risk of severe COVID-19. 12 Patients with chronic conditions may have a concomitant worsening of their underlying disease, including diabetic ketoacidosis and acute chest syndrome. 5 Co-infection with other viruses and bacteria is an important consideration. A metanalysis found that 5.6% of pediatric patients had a co-infection; within this group, 58% had Mycoplasma pneumoniae, 11 .1% had influenza A or B, 9.7% had respiratory syncytial virus, while the remainder had other common types of viral and bacterial infections. 11 Thrombotic complications from COVID-19 such as deep vein thrombosis and pulmonary embolism were seen in 2.1% of pediatric cases in a multicenter retrospective cohort study in the US, sometimes despite thromboprophylaxis. 14 In a metanalysis of pediatric cases, the most common laboratory findings were high ferritin and procalcitonin in around 25%, and high CRP in about 20%. 2 Mean CRP amongst pediatric cases of COVID-19 is estimated at 9.4 mg/L. 11 In contrast to adult cases, leukocyte count was normal in around 70% of cases, with 15% each having leukopenia or leukocytosis. 15 D-dimer, interleukin 6, and creatinine kinase may also be elevated. 11 In reported pediatric cases, chest x-ray were normal in roughly a third, while another third showed focal consolidations, and the remainder demonstrated ground glass opacities. 2, 11 A systematic review of chest early in the course of illness especially if there is no improvement after remdesivir and GC, and for those patients with impaired humoral immunity. Finally, antiplatelet and anticoagulation therapy should be considered to prevent thrombotic complications. Experts have recommended prophylactic low molecular weight heparin in children hospitalized for COVID-19 or MIS-C who are at higher risk for thrombosis, including elevated D-Dimer, risk factors for severe SARS-CoV-2 related disease, or risk factors for VTE, such as family history, obesity, and chronic inflammatory conditions. 22 A subset of adult patients develop high levels of inflammation around the second week of COVID-19, termed "COVID-19-associated hyperinflammatory syndrome" (cHIS) 23 . Frequent manifestations include fever, high ferritin, liver injury, hematologic abnormalities, coagulopathy, and high levels of inflammatory cytokines, specifically CRP and IL-6. There have been several adult trials for cHIS, primarily with tocilizumab, with conflicting results. 24, 25 Use of tocilizumab in pediatric COVID-19 has not been formally studied. The American College of Rheumatology (ACR) has issued guidelines for pediatric patients with COVID-19 who develop hyperinflammation; recommendations include anakinra, and consideration of other therapies with less evidence including GC and tociliuzumab. 26 Data is still emerging on the long-term outcomes after COVID-19 in children. In a small case series from China, repeat CT approximately 30 days after discharge showed that half of pediatric patients had imaging abnormalities, but dyspnea scores were all mild and improving, and no patients required oxygen. 27 In adults, "long COVID" has been described with symptoms of headache, fatigue, dyspnea, and anosmia lasting for weeks to months after infection. 28 The full spectrum of long COVID, or Post-Acute Sequelae of SARS CoV-2 infection (PASC), has not yet been fully characterized in children but efforts are underway. Currently, mRNA vaccines against SARS-CoV-2 have been approved for patients age 12 and older; large pediatric trials are assembled with results expected by summer 2021. Vaccination is recommended for eligible people who have had COVID-19, but delaying vaccination for 90 days after the acute illness is recommended. The ACR has issued guidance regarding medication management in children with rheumatologic disease in the setting of the SARS-CoV-2 pandemic. 29 Pediatric patients with chronic rheumatologic disease do not uniformly appear to be at higher risk of COVID-19. In adults, there is a higher odds of death in those with moderate to high rheumatologic disease activity and certain medications, including GC, rituximab, and sulfasalazine. 30 Similar data have not been reported in pediatric rheumatic diseases, but are being collected. To date, specific guidance has not been issued regarding SARS CoV-2 vaccination in pediatric rheumatology patients, but the ACR has recommended holding certain immunosuppressives for adults with rheumatic disease around vaccination. 31 J o u r n a l P r e -p r o o f Demographic Trends of COVID-19 cases and deaths in the US reported to CDC Prevalence, clinical characteristics, and outcomes of pediatric COVID-19: A systematic review and meta-analysis Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management Disparities in case frequency and mortality of coronavirus disease 2019 (COVID-19) among various states in the United States Characteristics and risk factors associated with critical illness in pediatric COVID-19 COVID-19 and multisystem inflammatory syndrome in children and adolescents Pediatric COVID-19: Systematic review of the literature Severe and fatal forms of COVID-19 in children COVID-19 in 7780 pediatric patients: A systematic review Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review and Meta-Analysis Risk Factors for Severe COVID-19 in Children Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood Laboratory abnormalities in children with novel coronavirus disease 2019 Imaging Findings of SARS-CoV-2 Infection in Pediatrics: A Systematic Review of Coronavirus Disease 2019 (COVID-19) in 850 Patients American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 2. Arthritis Rheumatol Pulmonary sequelae of pediatric patients after discharge for COVID-19: An observational study. Pediatr Pulmonol. 2021. 28 American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1 Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe Multisystem Inflammatory Syndrome in U.S. Children and Adolescents Hyperinflammatory shock in children during COVID-19 pandemic Health Department-Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States Multisystem inflammatory syndrome in children and adolescents with COVID-19 Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19 Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review Multisystem Inflammatory Syndrome in Children in New York State